Phase III study of ciclesonide nasal aerosol (74ug and 148ug in the morning) in patients 12 years or older with seasonal allergic rhinitis.
Phase of Trial: Phase III
Latest Information Update: 25 Feb 2013
At a glance
- Drugs Ciclesonide (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 25 Feb 2013 Results from a post-hoc analysis, which included data from this trial, have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology according to a Sunovion Pharmaceuticals media release.
- 28 Nov 2012 New trial record
- 12 Nov 2012 Results were presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), according to a Sunovion Pharmaceuticals media release.